|Bid||0.0000 x 900|
|Ask||0.0000 x 1400|
|Day's Range||3.3000 - 3.5500|
|52 Week Range||1.0000 - 10.5400|
|Beta (5Y Monthly)||3.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2020 - Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.13|
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 Mallinckrodt earnings conference call. Joining me this morning are Mark Trudeau, CEO; Steven Romano, our chief scientific officer; and Bryan Reasons, our CFO.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
-- Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 -- STAINES-UPON-THAMES, United Kingdom and GARDEN GROVE, Calif. ...
Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.
Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 17.07% and 3.99%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Mallinckrodt Plc (NYSE:MNK) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:30 ...
The proposed deal includes a Chapter 11 filing covering the generics unit and a resolution of claims from state and local governments, the newspaper said https://on.wsj.com/2SWoZXW, citing people familiar with the matter. The settlement would offer $1.6 billion to state and local governments over eight years and warrants to buy an equity stake in the company, according to the report. Mallinckrodt did not immediately respond to a Reuters request for comment.